Michael R. Bristow
Co-Founder & Member of the Scientific Advisory BoardDr. Michael R. Bristow, M.D., Ph.D., co-founded Oruka Therapeutics, Inc. (Formerly ARCA Biopharma, Inc. (formerly known as, ARCA Discovery, Inc.)) in September 2004 and had been Chief Executive Officer and President since July 10, 2009 until April 3, 2024. He serves as Member of Scientific Advisory Board at Renovacor, Inc. He is Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus. Previously, Dr. Bristow served as the President and Chief Executive Officer of ARCA biopharma, Inc. from September 2004 to November 2006. Dr. Bristow served as the Chief Science & Medical Officer of ARCA biopharma, Inc. from November 6, 2006 to July 10, 2009. He founded Gilead Colorado, Inc. and was its Scientific Advisor since February 2006. Dr. Bristow is the Professor of Medicine at the University of Colorado since October 1991. He co-founded Viridian Therapeutics, Inc. (Formerly known as Miragen Therapeutics, Inc.) in 2006. Dr. Bristow was one of the founders of Myogen, Inc. He served as Chief Science and Medical Officer of Myogen Inc. from October 1996 to February 2006. He served as Scientific Advisor to Myogen from February 2006 to November 2006. Dr. Bristow served as the Head of Cardiology at the University of Colorado Health Sciences Center and Co-Director of the University of Colorado Cardiovascular Institute. He served as the Chairman at ARCA biopharma, Inc. from November 6, 2006 to July 10, 2009. He was a Director of Gilead Colorado, Inc. (a/k/a Myogen Inc.) since October 1996. He has been a Member of Scientific Advisory Board of Viridian Therapeutics, Inc. (Formerly known as Miragen Therapeutics, Inc.) since January 2010. He had been a Director of ARCA biopharma, Inc. since September 2004 until 2024. He served as a Member of Scientific Advisory Board at Nile Therapeutics, Inc. since October 2010. Dr. Bristow served as a Member of the Scientific Advisory Board of Inverseon Inc. He is the author of over 300 peer-reviewed publications and chapters on heart failure or cardiomyopathy for cardiology textbooks, including Braunwald's "Heart Disease: A Textbook of Cardiovascular Medicine" and Hurst's "The Heart.". He moved to the University of Utah in 1984, where he co founded the first multi hospital heart transplant program in the US. He has received many academic and industry honors, including the Therapeutics Frontiers Award by the American college of Clinical Pharmacy (1993), the Pharmaceutical Research and Manufacturers of America Clinical Trial Exceptional Service Award (2008), the Lifetime Achievement Award by the Heart Failure Society of America (2008), Scientist of the Year by the Colorado Chapter of the ARCS Foundation (2008), University of Illinois Alumni Achievement Award, (2009) and the Distinguished Scientist Award (Translational Domain) by the American College of Cardiology (2014). Dr. Bristow holds an M.D. and PhD in pharmacology from the University of Illinois-Urbana-Champaign in 1970 and 1971 respectively. He completed an NIH postdoctoral fellowship in pharmacology at the University of Illinois and received his medical training at Stanford University.
Positions
- Company NameViridian Therapeutics, Inc.Stock CodeVRDNPositionCo-Founder & Member of the Scientific Advisory BoardColleagues
- SFStephen F. MahoneyCEO, President & Director
- TKTomas KiselakIndependent Chairperson of Board
- SHSeth HarmonChief Financial Officer
- TWThomas W. BeethamChief Operating Officer
- JTJennifer TousignantChief Legal Officer & Corporate Secretary
- RTRadhika TripuraneniChief Medical Officer
- ENEric N. OlsonCo-Founder & Chairman of Scientific Advisory Board
- MHMarvin H. CaruthersCo-Founder & Scientific Advisory Board Member
